Format

Send to

Choose Destination
Cancer Invest. 2016 Nov 25;34(10):517-520. Epub 2016 Nov 8.

Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer.

Author information

1
a Department of Internal Medicine , Loma Linda University Medical Center , Loma Linda , California , USA.
2
b Department of Medicine , Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College , New York , New York , USA.
3
c Department of Pharmacology , Faculty of Medicine, University of Helsinki , Helsinki , Finland.
4
d Antitumor Assessment Core Facility, Memorial Sloan-Kettering Cancer Center , New York , New York , USA.
5
e Department of Epidemiology and Statistics , Memorial Sloan-Kettering Cancer Center , New York , New York , USA.
6
f Department of Medicine , GU Oncology Service, Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College , New York , New York , USA.

Abstract

OBJECTIVES:

To investigate the tumor-suppressive properties of enzalutamide in androgen-driven ovarian cancer.

METHODS:

Mice were implanted subcutaneously with OVCAR-3 cells and treated with dihydrotestosterone in combination with enzalutamide or vehicle control. Tumor volumes were measured twice weekly until day 56.

RESULTS:

Dihydrotestosterone exposure led to a significant increase in tumor growth, while concomitant treatment with enzalutamide led to significant reductions in tumor volume compared to the androgen-exposed groups.

CONCLUSIONS:

We present the first evidence that the second-generation anti-androgen enzalutamide may possess efficacy in the treatment of ovarian cancer, paving the way for the future clinical trials.

KEYWORDS:

Enzalutamide; OVCAR-3; androgen receptor; epithelial ovarian cancer; xenograft

PMID:
27824515
PMCID:
PMC5546102
DOI:
10.1080/07357907.2016.1242598
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center